Immunocore’s (IMCR) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Immunocore (NASDAQ:IMCR) in a research report released on Monday,Benzinga reports. The brokerage currently has a $100.00 price objective on the stock.

A number of other research analysts have also recently weighed in on the stock. Morgan Stanley reiterated an “equal weight” rating and issued a $35.00 target price on shares of Immunocore in a research note on Friday, March 7th. Needham & Company LLC reiterated a “buy” rating and issued a $71.00 target price on shares of Immunocore in a research note on Thursday, April 10th. JPMorgan Chase & Co. dropped their target price on shares of Immunocore from $54.00 to $50.00 and set an “overweight” rating on the stock in a research note on Monday, April 14th. Deutsche Bank Aktiengesellschaft started coverage on shares of Immunocore in a research note on Tuesday, May 27th. They issued a “buy” rating and a $65.00 target price on the stock. Finally, Mizuho dropped their price target on shares of Immunocore from $38.00 to $33.00 and set a “neutral” rating on the stock in a research note on Monday, April 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $58.89.

Immunocore Stock Up 5.6%

IMCR opened at $38.65 on Monday. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The stock has a market cap of $1.94 billion, a price-to-earnings ratio of -40.68 and a beta of 0.75. Immunocore has a twelve month low of $23.15 and a twelve month high of $48.50. The company’s 50-day moving average price is $29.56 and its two-hundred day moving average price is $30.00.

Immunocore (NASDAQ:IMCR) last released its earnings results on Wednesday, May 7th. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.45. The firm had revenue of $125.13 million for the quarter, compared to analysts’ expectations of $108.82 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The company’s quarterly revenue was up 33.6% on a year-over-year basis. During the same period in the previous year, the company earned ($0.49) earnings per share. As a group, equities analysts expect that Immunocore will post -0.94 earnings per share for the current year.

Insider Activity at Immunocore

In other news, Director Bros. Advisors Lp Baker bought 807,338 shares of the stock in a transaction on Monday, March 17th. The shares were acquired at an average cost of $29.72 per share, for a total transaction of $23,994,085.36. Following the purchase, the director now directly owns 2,144,060 shares of the company’s stock, valued at $63,721,463.20. This trade represents a 60.40% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 10.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Immunocore

Several institutional investors and hedge funds have recently bought and sold shares of IMCR. GF Fund Management CO. LTD. purchased a new stake in Immunocore in the 4th quarter worth approximately $25,000. Oppenheimer Asset Management Inc. purchased a new stake in Immunocore in the 1st quarter worth approximately $225,000. China Universal Asset Management Co. Ltd. lifted its stake in Immunocore by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock worth $248,000 after purchasing an additional 960 shares in the last quarter. Checkpoint Capital L.P. purchased a new stake in Immunocore in the 1st quarter worth approximately $267,000. Finally, Banque Transatlantique SA purchased a new stake in Immunocore in the 1st quarter worth approximately $278,000. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.